Followers | 3819 |
Posts | 239240 |
Boards Moderated | 0 |
Alias Born | 07/30/2007 |
Wednesday, October 24, 2018 9:02:42 AM
9:00 AM ET 10/24/18 | BusinessWire
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer's Disease
Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit
HIGH POINT, N.C.--(BUSINESS WIRE)--October 24, 2018--
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer's disease (AD) and diabetes, today announced that a subgroup analysis from the azeliragon Phase 3 STEADFAST trial was presented at the 11(th) Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain. The data presented at the conference included post-hoc, positive data indicating a potential benefit of treatment with azeliragon in AD patients with type 2 diabetes. It is estimated that nearly 40 percent of Medicare beneficiaries age 65 and older with dementia also have diabetes (Alzheimer's Association. 2018 Alzheimer's Disease Facts and Figures).
In a poster presentation titled "Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial," researchers from vTv reviewed results from a post-hoc subgroup analysis from the company's STEADFAST trial. This subgroup included 55 patients with type 2 diabetes (defined by glycosylated hemoglobin (HbA1c) of greater than 6.5% at baseline; HbA1c greater than 7.7% was an exclusion criterion at screening) and a clinical diagnosis of Alzheimer's disease in the combined A-Study and B-Study of the STEADFAST trial. The azeliragon-treated group in the A-Study (n=18) demonstrated a 6.1 point benefit on ADAS-cog relative to the placebo group (n=8), which was nominally statistically significant (p = 0.005), and a 1.7 point benefit on CDR-sb relative to placebo (p = 0.08) after 18 months of treatment.
When conducting this subgroup analysis on pooled data from both the A-Study and B-Study and comparing change from baseline at 12 months (B-Study was discontinued at 12 months), the azeliragon subgroup (n=33) demonstrated a 3.5 point benefit on ADAS-cog (p = 0.01) relative to the placebo group (n=22), and a 0.7 point benefit on CDR-sb (p = 0.24) relative to placebo. A copy of the poster can be found on the publications page of the company's website.
"The association between diabetes and dementia is well documented and these findings are supported by the mechanism of action of azeliragon. The Receptor for Advance Glycation Endproducts (RAGE) has been implicated in both the pathogenesis of Alzheimer's disease and diabetic complications. These results, albeit from a smaller number of patients, reinforce this hypothesis and may open a new therapeutic approach for the treatment of not only dementia but also other complications of diabetes," said Carmen Valcarce, Chief Scientific Officer of vTv Therapeutics.
"We are encouraged by the positive benefits experienced by the diabetic patients in this study." said Steve Holcombe, Chief Executive Officer of vTv Therapeutics. "With over 400 million people with diabetes around the world who are at a higher risk of developing dementia, we think these findings warrant further investigation of this therapy for this unmet medical need," added Mr. Holcombe.
About Azeliragon
Azeliragon, also known as TTP488, is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts, RAGE. vTv Therapeutics discovered and developed azeliragon using its proprietary drug discovery platform, TTP Translational Technology(R). A broad range of human pathologic and experimental biologic investigation suggests that RAGE ligand interactions lead to sustained inflammatory states that play a role in chronic diseases such as diabetes, inflammation, and Alzheimer's disease.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders.
About STEADFAST
The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (A-Study and B-Study), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimer's disease. The 18-month study targeted enrollment of 800 patients (400 in each trial). The first trial enrolled patients in the United States and Canada who had a clinical diagnosis of mild Alzheimer's disease and an MRI consistent with this diagnosis. Enrollment of the second trial included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa. While in April and in June 2018 topline results were announced that the A-Study and the B-Study did not meet the co-primary endpoints and clinical trials were ended, subsequent post-hoc subgroup analyses have shown populations that experienced positive benefits.
Recent VTVT News
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT • PR Newswire (US) • 03/19/2024 12:30:00 PM
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:47:37 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/06/2024 12:52:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:04:31 PM
- vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:26:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:14:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:08:30 PM
- vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE • PR Newswire (US) • 02/22/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:26:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:28:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:21:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:23:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:22:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:19:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:31 PM
- vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:16 PM
- vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 01:00:00 PM
- vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 11/02/2023 12:00:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM